Immune reconstitution inflammatory syndrome (IRIS) is an increasingly recognized clinical entity emerging in the context of the restoration of the immune system after significant immunosuppression. As the patient's immune system regains its potency, IRIS may lead to a paradoxical clinical deterioration when intense inflammatory infiltrates are formed to eradicate an underlying subclinical infection. 1 The vast majority of the patients with IRIS are HIVinfected subjects, whose immune system recovers after the initiation of highly active antiretroviral therapy. 2 Infections associated with IRIS include those caused by Mycobacterium tuberculosis, Mycobacterium Avium-Intracellulare (MAI), Cryptococcus neoformans, CMV, JC virus and Candida. 1, 3 We report a case of IRIS in a non-HIV-positive patient, who developed a severe form of CNS IRIS after treatment of CML with allogeneic hematopoietic SCT (HSCT). (Table 1) .
In April 2005, nearly 2 years after the transplant and 8 months after the cessation of immunosuppressive treatment, the patient developed convulsions, and MR imaging of the brain showed multiple subcortical low-density lesions of 1-2 cm in diameter ( Figure 1 ). Antimicrobial therapy was started with broad-spectrum antibiotics and acyclovir. In addition, as fungal infection was suspected, a combination of liposomal ambisome (3 mg/kg) and voriconazole was administered. Despite the treatment, over the next Letter to the Editor 2 weeks the patient's condition worsened; he became disoriented, had myoclonic contractions of the whole body and his consciousness level deteriorated. The cerebral lesions on MRI were slightly expanded ( Figure 1) . A brain biopsy was taken and histological examination revealed fungal hyphae and aggregates of lymphocytes ( Figure 2) . In tissue culture, the fungus was identified as Candida parapsilosis. Four weeks after the initial neurological symptoms, the patient's condition deteriorated further; he became comatose and needed mechanical ventilation. At this stage, dexamethasone treatment was initiated and he started to recover. After 3 weeks, he could converse normally and had only mild residual motor symptoms. On neuropsychological examination 4 months after the initiation of the neurological sequelae, no residual cognitive symptoms remained and the patient has since returned to working life. Brain biopsy showed an increased number of inflammatory cells in the brain parenchyma (Figure 2a ). Both Gram and Ziehl-Neelsen stains were negative, but PAS staining showed Candida-like structures (Figure 2b ).This was confirmed by Grocott staining (Figure 2c) . Immunohistochemical studies showed white matter areas with numerous CD8-positive lymphocytes (Figure 2d ). A few CD4-positive lymphocytes were also observed (Figure 2e ). Anti-CD68-staining showed perivascular macrophages and rod-shaped microglial cells (Figure 2f) .
Patients undergoing allogeneic HSCT are treated with highly immunosuppressive therapy, first, to eradicate the disease and, second, to allow the engraftment of donor cells and to prevent GVHD; they are more heavily immunocompromised at the time of and after transplantation than are solid organ transplant patients. 4 Hence, they are high-risk patients, susceptible to opportunistic infections, despite the use of prophylactic or pre-emptive medications against viruses, parasites and fungae. 5 CNS Candida infections are rare. 6, 7 On MRI, they may manifest as small enhancing ring lesions (cerebral microabscesses), leptomeningeal enhancement (meningitis) or cerebral macroabscesses with surrounding edema. 6, 7 None of these features were present in our patient. Instead, he had non-enhancing, slightly expansive subcortical lesions. Such lesions have been described in cases of IRIS, 2, 3 although in many other CNS-IRIS cases, the MRI findings have shown intensive gadolinium enhancement. 2, 8, 9 The CNS symptoms of our patient emerged 8 months after complete cessation of immunosuppressive treatment (and half a year after the recovery of blood CD4 cells), a timing compatible with the onset of IRIS. Moreover, several antiepileptics were administered, including phenytoin, carbamazepine and sodium valproate and, owing to drug interactions, the trough level of antifungal voriconazole was found to be low (o0.5 mg/l). Consequently, the voriconazole dose was nearly doubled (700 mg/d), but by this time the patient had already recovered and had been discharged from the hospital. Hence, the CNS symptoms were probably alleviated not by the antifungal treatment, but more likely by the steroid treatment and resolution of the IRISassociated CNS inflammatory infiltrates. Theoretically, the putative anti-inflammatory effects of phenytoin might also have contributed to the favorable outcome of IRIS. 10 Diagnosis of a CNS infection is difficult, and identification of the infectious pathogen often requires a brain biopsy. In this case, the biopsy confirmed the presence of a weak fungal pathogen; Candida parapsilosis is considered the least virulent of the Candida species. 6 In addition, the immunohistochemical finding of tissue infiltration with CD8-positive lymphocytes was compatible with IRIS. 2 From a clinical point of view, awareness of IRIS is important. Optimal management of the various CNSassociated IRIS manifestations remains poorly defined and no treatment recommendations now exist for CNS-IRIS. Therapeutic intervention is initially directed against the specific infectious agent and may be supplemented by corticosteroids to suppress the exuberant and potentially destructive inflammatory response. 11 We stress the importance of recognizing CNS-IRIS as a part of the differential diagnostics in patients with worsening CNS symptoms and a preceding immunosuppressive state, including allogeneic HSCT.
